These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1777365)

  • 21. Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy.
    Raj PP; Aschhoff M; Lilly L; Balakrishnan S
    Indian J Lepr; 1988 Jul; 60(3):400-6. PubMed ID: 3058828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
    Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
    Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
    Edstein MD; Rieckmann KH; Veenendaal JR
    Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute dapsone intoxication: a case with prolonged symptoms.
    Elonen E; Neuvonen PJ; Halmekoski J; Mattila MJ
    Clin Toxicol; 1979; 14(1):79-85. PubMed ID: 436385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acetylator phenotyping: the effect of ethanol on the dapsone test.
    Hutchings A; Monie RD; Spragg B; Routledge PA
    Br J Clin Pharmacol; 1984 Jul; 18(1):98-100. PubMed ID: 6743494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of dapsone.
    Zuidema J; Hilbers-Modderman ES; Merkus FW
    Clin Pharmacokinet; 1986; 11(4):299-315. PubMed ID: 3530584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
    Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
    Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of Arylamine N-Acetyltransferase 2 Acetylation Genotype by PCR and Phenotyping Using Dapsone Through High-Pressure Liquid Chromatography Assay: A Gender Wise Study.
    Akhter N; Iqbal T; Jamil A; Akram M; Mehmood Tahir I; Munir N
    Dose Response; 2019; 17(2):1559325819855537. PubMed ID: 31285712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra-adipose administration of monoacetyldapsone to healthy volunteers.
    Pieters FA; Zuidema J
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):510-6. PubMed ID: 3819527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid acetylation phenotyping in Saudi Arabs.
    Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
    J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging.
    Korrapati MR; Sorkin JD; Andres R; Muller DC; Loi CM; Vesell ES; Vestal RE
    J Clin Pharmacol; 1997 Feb; 37(2):83-91. PubMed ID: 9055133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
    Morris RJ; Freed CR; Kohler PF
    Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-acetylation phenotyping with sulphadimidine in a Turkish population.
    Bozkurt A; Basci NE; Kalan S; Tuncer M; Kayaalp SO
    Eur J Clin Pharmacol; 1990; 38(1):53-6. PubMed ID: 2328748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylator phenotype in Iraqi patients with atopic dermatitis.
    Najim RA; Al-Waiz MM; Al-Razzuqi RA
    Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes.
    Irshaid Y; Adedoyin A; Lotze M; Branch RA
    Drug Metab Dispos; 1994; 22(1):161-4. PubMed ID: 8149877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal and biliary disposition of dapsone in the dog.
    Biggs JT; Uher AK; Levy L; Gordon RD; Peters JH
    Antimicrob Agents Chemother; 1975 Jun; 7(6):816-24. PubMed ID: 1155923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.